Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial.

By C. Bailey, J. Gross, A. Pieters, A. Bastien, J. List. The Lancet, 2010

875 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. (2012, background): “These suggestive events have been noted in previous studies with dapagliflozin, where they have responded to routine management and have rarely led to study discontinuation (12, 13).”
Update on the treatment of type 2 diabetes mellitus. (2016, methodology): “In phase 3 trials comparing placebo for 24 wk and dapagliflozin (2.5, 5 and 10 mg once daily) used alone or added to metformin [141] , pioglitazone [142] , glimepiride [143] or insulin [144] was observed that HbA1c and fasting plasma glucose in patients with T2DM was reduced.”
Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes (2013, background): “A decrease in plasma volume, with resultant haemoconcentration, could contribute to an increase in haematocrit as observed in the present and previous studies [8].”
Mechanisms of diabetic complications. (2013, background): “This is an insulin-independent approach to reduce plasma glucose levels currently being extensively evaluated in type 2 diabetes (31, 416).”